The pharmaceutical supply chainThe network of organizations, resources, and activities involved in the production and distribution of goods and services. More in North America has entered a new era defined by stricter regulations, more temperature-sensitive products, and the growing expectation of real-time visibility across every shipment, pallet, case, and vial. Since 2020, the market has expanded rapidly, reaching more than $180 billion in North America, driven by biologics, aging demographics, and the explosion of direct-to-patient healthcare models (Mordor Intelligence).

With high-value therapies, controlled environmental conditions, and zero tolerance for errors, pharmaceutical logisticsThe regulated planning, storage, handling, transportation, and distribution of pharmaceutical and healthcare products in compliance with GMP/GDP, temperature-control, traceability, and regulatory requirements to protect product quality and patient safety. More is no longer a generic 3PLThird-Party Logistics (3PL): A service provider that offers outsourced logistics services to companies, managing warehousing, transportation, and distribution. More service, it is a compliance-critical, risk-reduction function that directly influences patient safety and regulatory outcomes.

Hyperlink Logistics positions itself at the centre of this complexity, offering pharma-ready warehousingThe storage of goods in a facility equipped to handle inventory management and distribution. More and cross-border distributionThe regulated movement of pharmaceutical products between countries—particularly between Canada and the United States—requiring compliance with customs, security, temperature control, and traceability requirements in both jurisdictions. More built around Health Canada, the U.S. Food and Drug Administration (FDA), GMP/GDP standards, and the Drug Supply Chain Security Act (DSCSA).

What Pharmaceutical Logistics Really Means in 2026

Pharmaceutical logisticsThe regulated planning, storage, handling, transportation, and distribution of pharmaceutical and healthcare products in compliance with GMP/GDP, temperature-control, traceability, and regulatory requirements to protect product quality and patient safety. More is more than transportation and storage. It is a regulated operational system designed to protect drug quality, maintain chain-of-custody, and preserve product efficacy, especially for biologics, vaccines, and temperature-sensitive therapies.

Key functional components include:

GMP/GDP Warehousing

Drug products must be stored under Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), including environmental control, sanitation, training, and full audit readiness. Guidance such as Health Canada’s GUI-0069 outlines temperature management and transportation expectations for all parties, including 3PLs.

Serialization & DSCSA Compliance

The U.S. DSCSA mandates package-level traceability, 2D DataMatrix barcodes, electronic transaction records, and interoperable tracing systems across the entire U.S. supply chainThe network of organizations, resources, and activities involved in the production and distribution of goods and services. More. For 3PLs, that means DSCSA-ready systems, serial-level inventory control, and secure data exchange.

Product Scope

Hyperlink manages regulated healthcare categories including:
• Prescription and OTC drugs
• Biologics, biosimilars & vaccines
• Diagnostics & medical devices
• Nutraceuticals & natural health products
• Temperature-sensitive specialty therapies

Canada vs. U.S. Regulations: What a 3PL MUST Comply With

Canada: GMP, GDP & Temperature-Control Compliance

Health Canada requires 3PLs to meet the same fundamental quality expectations as manufacturers.

Environmental Control (GUI-0069)

Under GUI-0069, pharma warehouses and carriers must ensure:

• Continuous temperature monitoring
• Calibrated sensors and alarms
• Validated storage equipment
• Qualified packaging and shipping lanes
• Documented response to excursions

Drug Establishment Licensing Requirements

3PLs operating under a client’s Drug Establishment Licence (DEL)A Health Canada licence required for activities such as drug fabrication, packaging, labelling, testing, importing, and wholesaling, under which third-party logistics providers may operate when handling regulated pharmaceutical products. More must comply with GMP in areas such as:

• Training and competency
• Sanitation and pest control
• Documented SOPs
• QA oversight and internal audits
• Recall readinessThe operational and system capability to rapidly identify, isolate, and retrieve affected pharmaceutical products by lot or serial number in the event of a regulatory or voluntary recall. More and record retention

Quarantine & Segregation

Products that are returned, expired, damaged, or pending release must be held in quarantined, clearly separated areas to avoid mix-ups and inadvertent distribution.

Recall Readiness

Facilities must provide complete lot-level traceability and rapid isolation, aligned to Health Canada’s evolving recall expectations.

United States – FDA, DSCSA & 21 CFR Part 205

The U.S. regulatory framework, led by the FDA, prioritises product integrity, counterfeit prevention, and traceability.

21 CFR Part 205

21 CFR Part 205 sets minimum standards for prescription drug distributor licensing, including:

• Appropriate storage conditions
• Secure facilities and access control
• Examination of incoming and outgoing shipments
• Complete, auditable distribution records

DSCSA Package-Level Serialization

The DSCSA now requires:

• Unit-level 2D barcodes with serial, lot, and expiry
• Electronic transaction information and history
• Licensed, verified trading partners
• Interoperable tracing across the supply chainThe network of organizations, resources, and activities involved in the production and distribution of goods and services. More

USP <1079> Storage Definitions

USP <1079> clarifies CRT, refrigerated, frozen, and ultra-cold handling requirements, and how excursions must be assessed and documented.

Cross-Border Compliance

Pharmaceutical distribution between Canada and the U.S. demands specialised regulatory and operational expertise.

CTPAT & Chain-of-Custody Security

Participation in security programs such as CTPAT supports trusted trader status and reduced inspection rates, while reinforcing chain-of-custody discipline for high-value healthcare shipments.

Section 321 Opportunities (OTC/NHP Products)

De minimis clearance under Section 321A provision in the U.S. customs regulations that allows for duty-free importation of low-value shipments (valued at $800 or less) into the United States, provided certain conditions are met, such as the shipment being for personal use and not for resale. More can apply to consumer health shipments, enabling cost-efficient small-parcel entry into the U.S. when handled correctly. Guidance from providers such as Purolator outlines the operational boundaries and compliance constraints.

Customs-Bonded Warehousing

Customs-bonded warehouses allow goods to be stored prior to formal customs clearance, while still operating under full GMP/GDP controls. For pharma companies, this supports flexible inventory positioning for both Canadian and U.S. markets.

Protecting Cold Chain Across the Border

Border delays are a known risk driver for temperature excursions and product loss, particularly for biologics and vaccines. Cross-border pharma programs need qualified routes, extended-duration packaging, and proactive customs coordination.

Cold Chain Logistics: Managing the Highest-Risk Segment

Cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More failures cost the industry more than $35 billion annually, driven by product losses, excursions, and stability failures (Pharmaceutical Outsourcing).

Modern cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More logistics relies on:

Validated Temperature-Controlled Packaging

• Passive shippers offering 48–120+ hours of control
• Active powered containers for bulk or ultra-cold moves
• Gel packs, dry ice, and phase-change materials
• Climate-tolerant insulation designed for worst-case lanes

Real-Time Monitoring

IoT-enabled data loggers provide the following metrics:

• Live temperature and location
• Shock and light exposure data
• Real-time alerts for threshold breaches
• Data to support release, quarantine, or discard decisions

Temperature Excursion Management

Every deviation triggers immediate quarantine, investigation, and stability assessment. QA and regulatory requirements demand documented root cause analysis and CAPA.

Regulatory Alignment

Cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More processes are aligned to:

• Health Canada GUI-0069
• USP <1079>
• FDA expectations for storage, handling, and distribution

The Technology Stack Behind Compliant Pharmaceutical Logistics

Pharma-grade logistics in 2026 is inseparable from its digital infrastructure.

WMS With Pharma-Specific Controls

A pharma-ready WMS(Warehouse Management System) Software that runs warehouse operations—receipts, put-away, picking, packing, inventory accuracy.
Key for visibility and accurate customs data (quantities, lot numbers, etc.). More must support:

• Lot, batch, and expiry tracking
• FEFO-driven pick logic
• Storage-condition validation at putaway
• EPCIS-based serializationThe process of assigning a unique serial number to each saleable pharmaceutical unit, typically encoded in a 2D DataMatrix barcode, enabling verification, traceability, and compliance with DSCSA requirements. More handling
• Robust, reportable audit trails

Specialized platforms described by providers such as OLIMP illustrate these capabilities.

EDI & API Integrations

Tight integration with manufacturer ERP, wholesalers, and healthcare customers via EDI and modern APIs enables:

• Automatic order intake
• ASN and confirmation flows
• Real-time inventory visibility
• DSCSA-compliant data exchange

Environmental Monitoring & Alerts

24/7 sensor networks feed:

• Central dashboards for temperature and humidity
• Real-time alarm escalation (SMS, email, on-call)
• Evidence for inspections and audits

Cybersecurity & Retention Requirements

Regulators such as the FDA and Health Canada expect secure, validated systems with:

• access controls and role-based permissions
• business continuity and disaster recovery plans
• long-term retention of DSCSA and GMP records

Value-Added Services That Matter in Pharma Distribution

Leading 3PLs now extend beyond storage and transport into regulated finishing and market-support activities.

Repackaging & Relabeling

Under GMP conditions, pharma 3PLs provide:

• Secondary packaging
• Bilingual / market-specific relabeling
• DSCSA-compliant relabel operations

Kitting & Assembly

Clinical and commercial kits—starter packs, device-plus-drug bundles, and diagnostic kits—are assembled under documented SOPs with full component traceability.

GS1 Barcoding & Serialization Support

Services include:

• label design and printing
• GS1-compliant barcodingThe process of assigning and encoding data into barcode symbols, typically represented as a series of parallel lines or geometric patterns, for automatic identification and tracking of items, facilitating efficient inventory management and logistics operations. More
• aggregation and de-aggregation workflows

Temperature-Controlled Cross-Docking

Short-dwell handling in controlled docks and cross-dock areas minimises exposure risk for high-value biologics and vaccines.

Reverse Logistics & Controlled Destruction

3PLs manage:

• Handling of recalls and returns
• Segregation of expired or damaged products
• Coordination of controlled destruction with licensed waste partners

Competitive Landscape in North American Pharma Logistics

The market includes global integrators, wholesalers with logistics arms, and specialised healthcare 3PLs.

Key players include:

• UPS Healthcare – expanding cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More and healthcare capabilities, including the acquisition of Andlauer Healthcare Group in Canada
• DHL Life Sciences & Healthcare – GDP-certified global healthcare network
• FedEx Health – CEIV Pharma-certified hubs and cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More control towers
• Cencora / World Courier – global specialty logistics and clinical trial expertise
• McKesson and Cardinal Health – wholesale distribution with 3PLThird-Party Logistics (3PL): A service provider that offers outsourced logistics services to companies, managing warehousing, transportation, and distribution. More and specialty divisions
• Regional Canadian healthcare 3PLs and cold-chain specialists

Market analysis from firms such as Mordor Intelligence and Grand View Research shows continued growth and consolidation, especially around biologics, ultra-cold chainA specialised cold chain environment required for certain biologics, vaccines, and gene or cell therapies, typically maintained at −70°C or below, requiring specialised packaging, monitoring, and handling procedures. More, and direct-to-patient services.

Major Challenges in Pharma Logistics (and How Leading 3PLs Solve Them)

Cold Chain Failures

High-value biologics and vaccines are vulnerable to any deviation. Leading 3PLs tackle this with lane qualification, advanced packaging, and IoT monitoring, as highlighted in industry analysis by Pharmaceutical Outsourcing.

Regulatory Non-Compliance

Non-compliance can result in warning letters, product seizures, and licence suspensions. Solutions focus on robust quality systems, internal audits, and strong QA–operations integration.

Visibility Gaps

Visibility often drops beyond the primary DC. 3PLs address this with integrated WMS(Warehouse Management System) Software that runs warehouse operations—receipts, put-away, picking, packing, inventory accuracy.
Key for visibility and accurate customs data (quantities, lot numbers, etc.). More/TMS platforms, EPCIS-based serialisation, and real-time sensor feeds, improving chain-of-custody and recall readinessThe operational and system capability to rapidly identify, isolate, and retrieve affected pharmaceutical products by lot or serial number in the event of a regulatory or voluntary recall. More.

Border Delays

Delays at the border can destroy temperature-sensitive inventory. Border-savvy 3PLs combine bonded warehousingThe storage of goods in a facility equipped to handle inventory management and distribution. More, CTPATCustoms Trade Partnership Against Terrorism, a U.S. supply chain security program that enhances cross-border shipment security and can reduce inspection frequency for trusted partners. More participation, qualified routes, and proactive documentation to minimise this risk.

ESG and Sustainability Expectations

Healthcare’s environmental footprint is under increasing scrutiny. The World Health Organization has called for greener distribution, and logistics partners are responding with reusable packaging, energy-efficient facilities, and lower-emission fleets.

Why Pharmaceutical Companies Choose a Canadian 3PL Like Hyperlink

Pharmaceutical manufacturers increasingly rely on Canadian 3PLs for North American distribution because:

1. Rigorous Health Canada Standards

Health Canada’s GMP/GDP framework ensures a high baseline of quality, traceability, and environmental control that extends into 3PLThird-Party Logistics (3PL): A service provider that offers outsourced logistics services to companies, managing warehousing, transportation, and distribution. More warehouses.

2. Strategic Access to the U.S. Market

Canadian logistics hubs, especially in the Greater Toronto Area offer efficient reach into major U.S. markets, combined with cross-border expertise and access to mechanisms like Section 321A provision in the U.S. customs regulations that allows for duty-free importation of low-value shipments (valued at $800 or less) into the United States, provided certain conditions are met, such as the shipment being for personal use and not for resale. More for eligible consumer health products.

3. Superior Cold Chain Reliability

Canadian cold-chain infrastructure, backed by robust power grids and specialised healthcare 3PLs, provides a strong platform for biologics and vaccine distribution.

4. Cost-Effective, Compliance-Ready Warehousing

Canada offers a favourable mix of quality, cost, and labour stability, making Canadian GMP-aligned facilities an attractive option for regional North American distribution.

5. ESG-Aligned Operational Practices

Sustainability initiatives—such as reusable cold-chain packaging, green building practices, and cleaner transportation—align with the ESG goals of global pharmaceutical companies and guidance from organizations like the WHO.

Conclusion: The Right 3PL Turns Compliance Into Competitive Advantage

Pharmaceutical logisticsThe regulated planning, storage, handling, transportation, and distribution of pharmaceutical and healthcare products in compliance with GMP/GDP, temperature-control, traceability, and regulatory requirements to protect product quality and patient safety. More in 2026 demands:

• Zero-excursion cold chainA temperature-controlled supply chain designed to maintain pharmaceutical products within defined temperature ranges—commonly 2–8°C, frozen, or ultra-cold—from manufacturing through storage, transport, and final delivery. More performance
• Full DSCSA and GMP/GDP compliance
• High-visibility, traceable distribution
• Operational precision and audit readiness
• Cross-border regulatory fluency
• Alignment with ESG and sustainability goals

Hyperlink Logistics delivers these capabilities through pharma-grade warehousingThe storage of goods in a facility equipped to handle inventory management and distribution. More, validated cold-chain programs, and compliant cross-border fulfillment supporting manufacturers throughout Canada and the United States.

To schedule a pharma-compliance review or cross-border distributionThe regulated movement of pharmaceutical products between countries—particularly between Canada and the United States—requiring compliance with customs, security, temperature control, and traceability requirements in both jurisdictions. More assessment, contact Hyperlink Logistics.